High-Dose Propofol May Have Blunted Bupivacaine’s Cardiotoxic Effect During MAiD
A case from Canada raises a practical concern for clinicians performing medical assistance in dying with organ donation in mind: very high-dose propofol may have slowed the expected cardiotoxic action of bupivacaine. In this patient, the interval from the first medication to declaration of death stretched to 19 minutes, longer than the usual course for many MAiD procedures.
The case involved a 65-year-old woman with advanced rheumatoid arthritis, heterotopic ossification after total hip arthroplasty, and chronic pain. She met criteria for MAiD and wished to donate her organs. Because vascular access was difficult, a peripherally inserted central catheter was placed in the right basilic vein, allowing central venous delivery during the procedure. Her weight was 69 kg, and she had no known cardiopulmonary disease.
The procedure began with midazolam 10 mg intravenously for anxiolysis and lidocaine 40 mg intravenously for local analgesia. A first 1000 mg dose of propofol followed for coma induction, and respiratory arrest occurred shortly thereafter. The team then administered bupivacaine 400 mg intravenously and rocuronium 200 mg intravenously. Even after respiratory arrest, the heart did not immediately progress to asystole. About 8 minutes into the procedure, heart rate rose while the QRS complex remained narrow, then slowed again with the QRS still narrow.
A second 1000 mg dose of propofol was given because the procedure was taking longer than intended. After that second dose, bradycardia appeared, QRS widening followed, and asystole developed several minutes later. Death was confirmed 5 minutes after asystole began, in keeping with standard practice for donation after circulatory criteria. Both lungs and kidneys were successfully procured.
The sequence is clinically important because bupivacaine is used in some Canadian MAiD protocols to shorten time to asystole. A prolonged interval can increase warm ischemic time in organ donation pathways and can also prolong the emotional burden for family members witnessing the procedure. Canadian MAiD activity is substantial; in 2024, 16 499 people received MAiD, a 6.9% rise from the prior year. In most patients, the procedure lasts about 10 minutes, but preserved cardiopulmonary function can make death take much longer.
A Lipid Emulsion Effect Is Plausible, Not Proven
The authors point to a biologically plausible explanation for the delayed effect of bupivacaine: the massive lipid load delivered through propofol. Propofol is formulated as a 1% emulsion containing soybean oil, purified egg phospholipids, and glycerol. In toxicology practice, lipid emulsion is used to treat local anesthetic systemic toxicity, and bupivacaine is one of the best recognized triggers of that syndrome.
The mechanism is not speculative fluff; it has a pharmacologic basis. Lipid emulsion can sequester lipophilic drug away from cardiac tissue, moving it into an intravascular lipid compartment and redistributing it toward organs involved in storage and metabolism. It may also improve cardiac performance through direct cardiotonic effects. In standard toxicology care, this strategy can reverse cardiovascular collapse from local anesthetic exposure.
Here, the patient received 2000 mg of propofol in roughly 3 minutes, equivalent to 20 g of lipids or 200 mL of a 10% lipid emulsion, about 2.9 mL/kg. The authors compare this to the lipid dose used therapeutically for local anesthetic systemic toxicity. In that setting, the timing and quantity of lipid administration matter because they can blunt the cardiovascular toxicity of bupivacaine. The same principle could explain why the expected rapid asystole did not occur on schedule.
One sentence captures the concern: a drug chosen to hasten cardiac arrest may have been partially neutralized by the vehicle used to induce coma.
Bupivacaine, Propofol, and the Organ-Donation Consequence
Other explanations remain possible. Propofol itself can cause profound cardiovascular depression, which may have reduced cardiac output and delayed drug delivery from the central venous system to the coronary circulation. Although the catheter tip was positioned centrally, severe hemodynamic compromise could still have slowed transport. Unmeasured hypotension is another possibility, since blood pressure and cardiac output were not recorded during the procedure.
Late QRS widening may have represented delayed bupivacaine toxicity, but it may also simply have reflected terminal cardiorespiratory collapse. The case cannot prove causation. It does, however, connect a pharmacologic mechanism to a bedside problem that matters in MAiD protocols: delay in asystole is not merely a timing issue, especially when organ donation follows circulatory death.
Bupivacaine is widely used in Canada in this setting. A cross-sectional study cited in the article found that 24.3% of MAiD patients received cardiotoxic medications to shorten the procedure, and bupivacaine accounted for 83.7% of those cases. Potassium chloride is another option, but Canadian guidance does not recommend it as a routine cardiotoxic agent because of limited availability, the risk of pain with peripheral administration, and possible muscle spasms despite neuromuscular blockade.
Practical Choices for MAiD Protocols
The case leaves clinicians with a concrete caution. When bupivacaine and very high-dose propofol are used together, the lipid emulsion in propofol may reduce the cardiotoxic effect that some MAiD protocols rely on to achieve rapid asystole. In patients undergoing organ donation after MAiD, that delay can lengthen warm ischemic time and complicate the procedure.
Alternative choices already exist. Phenobarbital is permitted in protocols across Canada and may substitute for propofol as a coma-induction agent. When a central catheter is available and organ donation is planned, high-concentration potassium chloride may be considered instead of bupivacaine as the cardiotoxic agent. Those options avoid at least one plausible lipid-mediated interaction, although each comes with its own procedural and ethical considerations.
The report’s bottom line is cautious and appropriately restrained: this was a single case, and the interaction remains possible rather than established. Still, the sequence of events is hard to ignore. A larger body of observation is needed to determine whether high-dose propofol can reliably delay bupivacaine-induced asystole in MAiD protocols, how often the interaction occurs, and whether protocol changes should follow.